News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Any Sanofi-Aventis (France) Deal For Genzyme Corporation May Take Time, At Limited Price
August 19, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Wall Street Journal -- NEW YORK (Dow Jones)--French drug maker Sanofi-Aventis SA's (SNY, SAN.FR) pursuit of Genzyme Corp. (GENZ) is more likely to be a drawn out engagement rather than a shotgun wedding, and there may be other suitors.
Twitter
LinkedIn
Facebook
Email
Print
Alliances
Mergers & acquisitions
Sanofi
MORE ON THIS TOPIC
Artificial intelligence
Genentech makes $1.5B+ deal with AI heavyweight Earendil for cancer bispecifics
September 25, 2026
·
2 min read
·
Tristan Manalac
Manufacturing
FDA slams GLP-1 compounder over risk of contaminating drugs ‘with filth’
September 24, 2026
·
2 min read
·
Nick Paul Taylor
Acadia slides on Phase 2 miss in Alzheimer’s psychosis but keeps moving asset forward
September 24, 2026
·
2 min read
·
Gabrielle Masson
Funding
Backed by NVIDIA, Basecamp bags $140M to advance AI-designed drugs
September 24, 2026
·
1 min read
·
Tristan Manalac